Considering the patient’s persistent hyperglycemia and the maternal history of thyroid cancer, which made Glucagon-Like Peptide-1 receptor agonists (GLP1-RA) less suitable, empagliflozin therapy was initiated at a dose of 10 mg daily, while maintaining metformin therapy. The gene discussed is GLP1R; the disease is thyroid gland carcinoma.